Archon Bio is a biotechnology company developing geometrically tunable protein therapeutics that target pathways other technologies cannot. The company is recognized for its innovation in computationally designed biologics.

Archon Biosciences

Archon Bio

Archon Biosciences | 1,193 followers on LinkedIn. Pioneering next-generation antibody therapies with AI and computational protein design  | Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease.  

We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Senior Associate Scientist at Archon Bio

Justin Hare

Sr. Scientist, Immunology

Christie Mortales

Head of Research

Jonathan Graves

Senior Scientist - Biology Lead

Justin Huard

Although we emerged from stealth yesterday, our technology and vision has been developed for over a decade. Beyond innovative science, great biotechs are built on great relationships. We wouldn’t be here today without Madrona ’s conviction and belief in us since day one. Their leadership in AI-driven biotech and commitment to the transformational potential of Antibody Cages (AbCs) have enabled Archon to become a reality. We’re excited to continue this partnership and apply generative protein design to build best-in-class medicines together!

Today, Archon Biosciences announced $20 million in seed financing led by Madrona and shared our vision for the future of drug development! We’ve built a completely novel class of biologics, Antibody Cages (AbCs) designed to unlock powerful therapeutic targets beyond the reach of existing modalities and to better treat disease. AbCs integrate the unparalleled binding properties of antibodies into a boundless set of AI-generated nanostructures that have never existed in nature. Precise control over AbC structures provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold standard for biologic medicines. Learn more in our press release here: https://lnkd.in/eTJxYNuk To see AbCs in action and learn more about how Archon is applying generative protein design to improve human health, visit our website at https://www.archon.bio/ #biotech #antibodies #AI #ComputationalProteinDesign #AbC

ARCH

BIO:ARCHON

Archon Bio

locale

market

industry

website

crunchbase

linkedin

investor of

Metrics